Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 Your complete learning platform for speakers of 21 languages: Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Colorectal Neoplasms

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 37 articles: HTML format

Single Articles

December 2026
1. CREMOLINI C, Chalabi M, Elez E, Fassan M, et al
   Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
   Ann Oncol. 2026 Dec 31:S0923-7534(26)00108-0. doi: 10.1016/j.annonc.2026.
   PubMed    
   
   
   April 2026
2. CHEN X, Qiu MY, Zhang JP, Xia YD, et al
   Colorectal cancer detection using non-contrast CT and deep learning: a multicenter and international cohort study.
   Ann Oncol. 2026 Apr 21:S0923-7534(26)00150-X. doi: 10.1016/j.annonc.2026.
   PubMed     Abstract available
   
   
   December 2025
3. CIARDIELLO D, Martini G, Bielo LB, Pietrantonio F, et al
   Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.
   Ann Oncol. 2025 Dec 22:S0923-7534(25)06334-3. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   October 2025
4. GERMANI MM, Modest DP
   Response to 'A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer'.
   Ann Oncol. 2025 Oct 21:S0923-7534(25)04784-2. doi: 10.1016/j.annonc.2025.
   PubMed    
   
   
   
5. CANN C, Eng C
   Positioning EGFR re-treatment in modern metastatic colorectal cancer: insights from PARERE.
   Ann Oncol. 2025 Oct 18:S0923-7534(25)04952-X. doi: 10.1016/j.annonc.2025.
   PubMed    
   
   
   
6. CIRACI P, Germani MM, Pietrantonio F, Manca P, et al
   Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.
   Ann Oncol. 2025 Oct 18:S0923-7534(25)04934-8. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
7. SELIGMANN JF, Morton D, Elliott F, Handley K, et al
   Corrigendum to "Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population": [Ann Oncol 36 (2025) 520-528].
   Ann Oncol. 2025 Oct 9:S0923-7534(25)04703-9. doi: 10.1016/j.annonc.2025.
   PubMed    
   
   
   September 2025
8. TIAN H, Zhang RX, Zhang D
   A Temporal Paradox in the Proposed Risk-Adjusted Surveillance Algorithm for Metastatic Colorectal Cancer.
   Ann Oncol. 2025 Sep 26:S0923-7534(25)04783-0. doi: 10.1016/j.annonc.2025.
   PubMed    
   
   
   
9. SALAZAR R, Carmona-Bayonas A
   Toward risk-adjusted CT schedules in first-line metastatic colorectal cancer.
   Ann Oncol. 2025 Sep 23:S0923-7534(25)04780-5. doi: 10.1016/j.annonc.2025.
   PubMed    
   
   
   
10. LEPAGE C, Phelip JM, Cany L, Barbier E, et al
    Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer.
    Ann Oncol. 2025 Sep 17:S0923-7534(25)04701-5. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    August 2025
11. GERMANI MM, Heinemann V, Rossini D, Fischer von Weikersthal L, et al
    Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO.
    Ann Oncol. 2025 Aug 19:S0923-7534(25)00921-4. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
12. BAROT S, Liljegren A, Nordenvall C, Blom J, et al
    Incidence Trends and Long-Term Survival in Early-Onset Colorectal Cancer: A Nationwide Swedish Study.
    Ann Oncol. 2025 Aug 13:S0923-7534(25)00920-2. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    June 2025
13. HUANG YQ, Chen XB, Cui YF, Yang F, et al
    Enhanced risk stratification for stage II colorectal cancer using deep learning-based CT classifier and pathological markers to optimize adjuvant therapy decision.
    Ann Oncol. 2025 Jun 4:S0923-7534(25)00766-5. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available
    
    
    
14. RIEDL JM, Fece de la Cruz F, Lin JJ, Parseghian C, et al
    Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors.
    Ann Oncol. 2025;36:682-692.
    PubMed     Abstract available
    
    
    May 2025
15. WILLIAMS H, Fokas E, Diefenhardt M, Lee C, et al
    Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials.
    Ann Oncol. 2025;36:543-547.
    PubMed     Abstract available
    
    
    February 2025
16. BARON D, Pace Loscos T, Schiappa R, Barbet N, et al
    A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial.
    Ann Oncol. 2025;36:208-215.
    PubMed     Abstract available
    
    
    January 2025
17. SELIGMANN JF, Morton D, Elliott F, Handley K, et al
    Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II population.
    Ann Oncol. 2025 Jan 11:S0923-7534(25)00002-X. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    December 2024
18. MARTINEZ-CASTEDO B, Camblor DG, Martin-Arana J, Carbonell-Asins JA, et al
    Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy.
    Ann Oncol. 2024 Dec 13:S0923-7534(24)04981-0. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
19. CANDIA L, Cervantes A, Martinelli E
    Updated treatment recommendations for third and further lines of treatment in advanced colorectal cancer: from the ESMO Metastatic Colorectal Cancer Living Guideline.
    Ann Oncol. 2024 Dec 3:S0923-7534(24)04952-4. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
20. ANDRE T, Shiu KK, Kim TW, Jensen BV, et al
    Pembrolizumab Versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study.
    Ann Oncol. 2024 Dec 2:S0923-7534(24)04949-4. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
21. BEEHUAT TAN I, Lui R, Yan K, Lam R, et al
    Investigating the 'liquid-solid interface' in the comprehensive genomic profiling of metastatic colorectal cancer for guiding treatment-where do we draw the line?
    Ann Oncol. 2024;35:1067-1070.
    PubMed    
    
    
    November 2024
22. DE WILT JHW, van der Kruijssen DEW, Koopman M
    Reply to Letter to the Editor "Optimising Treatment Strategies in Metastatic Colorectal Cancer: Insights from CAIRO4" by Guzel et al.
    Ann Oncol. 2024 Nov 4:S0923-7534(24)04052-3. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
23. KATAOKA K, Mori K, Nakamura Y, Watanabe J, et al
    Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY.
    Ann Oncol. 2024;35:1015-1025.
    PubMed     Abstract available
    
    
    
24. BERCZ A, Park BK, Pappou E, Nemirovsky D, et al
    Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy.
    Ann Oncol. 2024;35:1003-1014.
    PubMed     Abstract available
    
    
    October 2024
25. GUZEL HG, Ilhan Y, Onder AH
    Optimising Treatment Strategies in Metastatic Colorectal Cancer: Insights from CAIRO4.
    Ann Oncol. 2024 Oct 10:S0923-7534(24)04053-5. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
26. ROMESSER PB, Cercek A
    Optimizing Rectal Cancer Treatment: A Path Towards Personalization.
    Ann Oncol. 2024;35:831-835.
    PubMed    
    
    
    
27. CONROY T, Castan F, Etienne PL, Rio E, et al
    Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.
    Ann Oncol. 2024;35:873-881.
    PubMed     Abstract available
    
    
    
28. LIN ZY, Zhang P, Chi P, Xiao Y, et al
    Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial.
    Ann Oncol. 2024;35:882-891.
    PubMed     Abstract available
    
    
    August 2024
29. CIARDIELLO D, Bielo LB, Napolitano S, Martinelli E, et al
    Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF(V600E) wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial.
    Ann Oncol. 2024 Aug 28:S0923-7534(24)03914-0. doi: 10.1016/j.annonc.2024.08.2334
    PubMed     Abstract available
    
    
    
30. ROS J, Matito J, Villacampa G, Comas R, et al
    Corrigendum to "Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments": [Annals of Oncology 34 (2023) 543-552].
    Ann Oncol. 2024 Aug 12:S0923-7534(23)00796-2. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    July 2024
31. BIONDO S, Frago R, Kreisler E
    Primary tumor resection for asymptomatic colorectal cancer with unresectable metastasis: the end of the dilemma.
    Ann Oncol. 2024 Jul 3:S0923-7534(24)00767-1. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
32. CECCHINI M, Sundar R
    Proofreading the way: immune checkpoint inhibitors in polymerase epsilon/polymerase delta (POLE/POLD1)-altered colorectal cancer.
    Ann Oncol. 2024;35:582-584.
    PubMed    
    
    
    June 2024
33. VAN DER KRUIJSSEN DEW, Elias SG, van de Ven PM, van Rooijen KL, et al
    Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.
    Ann Oncol. 2024 Jun 7:S0923-7534(24)00722-1. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    May 2024
34. AMBROSINI M, Rousseau B, Manca P, Artz O, et al
    Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
    Ann Oncol. 2024 May 3:S0923-7534(24)00104-2. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
35. BRENNER H, Niedermaier T, Hoffmeister M
    Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms.
    Ann Oncol. 2024;35:476-477.
    PubMed    
    
    
    April 2024
36. KELSEN D, Ben-Aharon I, Gordon N
    Identifying Genetic Loci Associated with an Increased Risk for Early Onset Colorectal Cancer.
    Ann Oncol. 2024 Apr 3:S0923-7534(24)00106-6. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    February 2024
37. LASKAR RS, Qu C, Huyghe JR, Harrison T, et al
    Genome-wide association study and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer.
    Ann Oncol. 2024 Feb 24:S0923-7534(24)00058-9. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum